Thermo Fisher Scientific Announces Partnership with Megaware to Deliver New Bioequivalence Solution
Thermo Fisher Scientific Inc. announced a new strategic partnership with Megaware, a life science technology organization, to deliver a new bioanalysis/equivalence solution and joint support services for pharmaceutical, biotech and contract research Organizations (CROs).
Under the terms of the collaboration, Thermo Fisher and Megaware will market a new comprehensive end-to-end software solution which provides bioequivalence functionality on a single platform to help speed up and manage clinical trials. According to the company, rapid market growth in generic drug production is driving the requirement for fast efficient bioequivalence studies to meet FDA ANDA guidelines (Abbreviated New Drug Applications). A unified software solution shall aggregate disparate software systems for organizations that demand tools to speed service and management of this critical and regulated IPO.
The two companies will work together closely to target the market for bioanalysis/equivalence studies, initially in India and thereafter across the Far East and other markets. The market in India for clinical trials is growing rapidly, because the average cost of trials is significantly lower than in the United States and Europe. The consultancy firm McKinsey estimates that US and European pharmaceutical companies will spend US $1.5 billion per year on clinical trials in India by 2010.
Thermo Fisher and Megaware will jointly sell, market and support the new solution in the field. Thermo Fisher will bring its bioanalytical expertise to the partnership and Megaware, with headquarters in Westborough, MA and Mumbai, India, will deliver the end-to-end technological focus combined with on-the-ground market knowledge. The new solution will offer higher throughput, greater levels of compliance and standardization of bioequivalence processes.
Most read news
Topics
Organizations
Other news from the department business & finance
These products might interest you
Get the analytics and lab tech industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Neandertal genome project reaches its goal - High-quality Neandertal genome provides novel insights into human origins
Opening the cavity floodgates - Biochemists investigate the transport of large proteins through bacterial cell membranes
Watermelon genome decoded - Decoded genome paves way for better watermelons
BIO White Paper Dispels Over-Patenting Myth - Patenting is a Critical Element in Fostering Research and Development
Dow acquires Rohm and Haas, creating world's leading specialty chemicals and advanced materials company - $18.8 billion transaction marks pivotal point in Dow's transformation
Cells stop dividing when this gene kicks into high gear
Targeted test for antibiotic resistance in clinical Enterobacter species - New discovery enables targeted antibiotic therapy
Varian, Inc. Announces Unique Probe Technology Breakthrough for Biological Solids NMR
Breakthrough Discovery Sheds Light on Heart and Muscle Health - Scientists shoot first true-to-life 3D image of the thick filament of mammalian heart muscle
Diagnosis just a breath away with new laser
MIT nanotubes sniff out cancer agents in living cells - Chemical engineers use carbon nanotubes to monitor chemotherapy, detect toxins at the single-molecule level